The generic name of Anrotinib is Anrotinib Hydrochloride, which is an anti-angiogenesis targeted drug with some reactions, but its adverse reactions are not considered to be big compared with traditional chemotherapy drugs.
Anrotinib hydrochloride is a new type of small molecule multi-target tyrosine kinase inhibitor, which can inhibit the activity of abnormal genes that are highly expressed in many kinds of tumor cells, to achieve the therapeutic effect of killing tumor cells, with less effect on normal cells. It can be used in the treatment of non-small cell lung cancer, thyroid cancer, gastric cancer, esophageal cancer, nasopharyngeal cancer and so on.
As a kind of targeted drug, Anrotinib hydrochloride also has some adverse reactions, the most common adverse reaction is gastrointestinal irritation symptoms, in addition, a small number of patients will have hypertension, hyperlipidemia, hepatic and renal function impairment, thyroid function abnormality and so on. Long-term use of the drug patients need to carry out regular follow-up review.
Compared with traditional chemotherapeutic drugs, the chemotherapeutic response of new targeted drugs is relatively small, and the majority of patients have good tolerance.
This product should be used in accordance with medical advice.